Naloxone’s rising price costing lives

naloxHospira, the sole manufacturer of opiate overdose reverser naloxone, has jacked up the price of the antidote by 1,110% since 2008, threatening the sustainability of overdose prevention programs nationwide, according to this article. Naloxone distribution programs have handed out more than 53,000 naloxone kits and report over 10,000 overdose reversals since 1996, the article notes — but in the past two years alone, almost 10% of the distribution programs have closed their doors, causing overdose deaths to start to bounce back up.

Possible solutions: the FDA could allow temporary importation of naloxone from foreign manufacturers, the federal government could lower prices by enticing new pharmaceutical companies to enter the market through a fast-track approval process, or the FDA could give the green light to naloxone for over-the-counter use so that people who need it can purchase directly from pharmacies, the article says.

Of course, Hospira could also lower the price of naloxone, which is a $20-million-a-year industry: it would cost a mere $100,000 for Hospira to supply every harm reduction program in the country with enough naloxone to meet current capacity, the article points out.

About Erin Marie Daly

I’m a freelance journalist based in San Francisco. My book on prescription drug and heroin addiction was published in August 2014 by Counterpoint Press.
This entry was posted in Informational, Pharmaceutical Industry, Trends and tagged , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *